SCHEMBL7258261

SCHEMBL7258261

NC(=O)C1=CN2CCOc3cccc(c32)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.36
NOTUM Q6P988 2/20 0.35
AHR P35869 1/20 0.33
MCL1 Q07820 1/20 0.33
TSHR P16473 1/20 0.32
RIPK1 Q13546 1/20 0.31
PRMT5 O14744 2/20 0.31
POLB P06746 2/20 0.31
KMT2A Q03164 1/20 0.31
ALDH1A1 P00352 2/20 0.31
HPGD P15428 1/20 0.31
DRD2 P14416 2/20 0.31
HTR2A P28223 2/20 0.31
HTR2C P28335 2/20 0.31
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
HTT P42858 1/20 0.30
HIF1A Q16665 1/20 0.30
TAAR1 Q96RJ0 1/20 0.30
PARP2 Q9UGN5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9273390 0.88 MCL1 (0.39) NOTUMAHRMCL1TSHRRIPK1
SCHEMBL9037611 0.76 MCL1 (0.34) NOTUMAHRMCL1TSHRRIPK1
SCHEMBL6843181 0.75 NPSR1 (0.45) TSHRPOLBKMT2AALDH1A1HPGD
SCHEMBL28414326 0.73 NOTUM (0.31) NOTUMALDH1A1HPGD
SCHEMBL7262363 0.70 PARP1 (0.31) PARP1
SCHEMBL7262595 0.69 HASPIN (0.32)
SCHEMBL30540811 0.69 CA12 (0.39) TSHRKMT2AALDH1A1HPGD
SCHEMBL7262745 0.69
SCHEMBL7262594 0.69
SCHEMBL9680591 0.69 TRPA1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299395-A1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2003-04-09 EP claimed
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections PHARMACIA & UPJOHN COMPANY 2002-08-01 US claimed
WO-2002004462-A1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2002-01-17 WO claimed
EP-1299395-A1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2003-04-09 EP disclosed
WO-2002004462-A1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections ZC3HAV1, RPL5, ZC3HAV1L PARP1 2058/4885NOTUM 2701/4885AHR 4458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.